Figure 5.

Acute LRRK2 kinase inhibition. (A) Representative western blots of healthy control and LRRK2 G2019S patient-derived LCLs treated for 1.5 h with RA334. (B) Quantification of western blots demonstrated that RA334 decreased LRRK2 pSer935 levels at all doses tested. (C) Representative western blots of healthy control and LRRK2 G2019S patient-derived LCLs treated for 1.5 h with RA283. (D) Quantification of western blots demonstrate that RA283 decreased LRRK2 pSer935 levels at all doses tested. All experiments were performed with at least three biological replicates (6 cell lines total), each performed in technical replicate. Data are presented as mean ± SEM. (*p < 0.001, determined by one-way ANOVA with a Tukey’s post-hoc comparison). Full blots available in Supplemental Figs. S14 and S15.